Actively Recruiting
Evaluating the Safety and Effectiveness of Elafibranor Compared to Placebo in Adults with Primary Sclerosing Cholangitis in a Randomized, Double-Blind Phase III Trial
Led by Ipsen · Updated on 2026-10-23
350
Participants Needed
231
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying how well and safely elafibranor works compared to a placebo in adults with Primary Sclerosing Cholangitis PSC, a rare liver disease that causes inflammation and scarring of the bile ducts. PSC can lead to serious liver damage, potentially requiring a liver transplant or causing death. This phase III study involves about 350 participants with large duct PSC. Participants will be randomly assigned to take either elafibranor 120 mg once daily or a placebo tablet daily. The study includes a screening period, a treatment period expected to last about 5 years until enough health events occur, and a post-treatment safety follow-up lasting around four weeks. The study is double-blind, meaning neither participants nor researchers know which treatment is given. Throughout the study, participants will have routine clinical assessments, lab tests, imaging evaluations, and patient-reported assessments to monitor disease progression, symptoms like pruritus and fatigue, quality of life, and safety. Researchers will measure event-free survival and monitor for adverse events and changes in vital signs and lab parameters. Participants may withdraw anytime, and the total study duration may extend over several years.
CONDITIONS
Brief Title
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
Research Team
I
Ipsen Clinical Study Enquiries
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here